Mark Albertella

Company: AstraZeneca

Job title: Senior Director - Oncology Bioscience

Seminars:

Addressing Project Optimus: Use of Preclinical, Modelling, & Clinical Data to Identify the Optimal Dose of the PARP1-Selective Agent Saruparib for Phase 3 Studies 9:30 am

Interrogating in vitro models to understand mechanisms of action and exposure thresholds for activity Analysing in vivo models to understand dose responses and exposure relationships needed for optimal efficacy Exploring mathematical quantitative systems pharmacology modeling to correlation of clinical exposures, PD and efficacy in relation to preclinical data and modeling Understanding how cross-validation of preclinical…Read more

day: Conference Day 2